acebutolol (sectral) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Acebutolol is a cardioselective, beta-adrenoreceptor blocking agent, which possesses mild intrinsic sympathomimetic activity (ISA) in its therapeutically effective dose range. Acebutolol is marketed under the trade names Sectral, Prent. Acebutolol is indicated for the management of hypertension in adults. It may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. Acebutolol is also indicated in the management of ventricular premature beats; it reduces the total number of premature beats, as well as the number of paired and multiform ventricular ectopic beats, and R-on-T beats. Acebutolol is a selective β1-receptor antagonist. Activation of β1-receptors by epinephrine increases the heart rate and the blood pressure, and the heart consumes more oxygen. Acebutolol blocks these receptors, lowering the heart rate and blood pressure. This drug then has the reverse effect of epinephrine. In addition, beta blockers prevent the release of renin, which is a hormone produced by the kidneys which leads to constriction of blood vessels.   NCATS

Chemistry

  • SMILES: CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(C(C)=O)c1
  • InChIKey: GOEMGAFJFRBGGG-UHFFFAOYSA-N
  • Mol. Mass: 336.43
  • ALogP: 2.37
  • ChEMBL Molecules:
    acebutolol  
    acebutolol hydrochloride  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.6335 - $0.8148
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

3'-acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide | 5'-butyramido-2'-(2-hydroxy-3-isopropylaminopropoxy)acetophenone | acebut hcl | acebutolol | (+/-)-acebutolol | (±)-acebutolol | acebutolol hcl | acebutolol hydrochloride | acebutololum | acetobutolol | dl-acebutolol | il-17803a | m&b-17803a | n-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]butanamide | n-(3-acetyl-4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl)butanamide | (rs)-acebutolol | sectral | sectral 200 | sectral 400

Organizations (12)

Research & Development (6)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (6)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (8)

Approved Indications (3)


 

Arrhythmias, Cardiac

Hypertension

Tachycardia, Ventricular (approved 1984)

Experimental Indications - Clinical Trial Phases 1-4 (6)


 

Cardiovascular Diseases (Phase 2)

Healthy Volunteers (Phase 4)

Heart Diseases (Phase 2)

Hemangioma (Phase 3)

Hypertension (Phase 2)

Vascular Diseases (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial Organizations: 6

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue